Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
Featuring subject matter experts in neuroscience, migraine and hypercholesterolemia
DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it will host its first in-person and virtual Analyst and R&D Day in New York on Thursday, November 10, 2022 from 8:30 a.m. to 12:30 p.m. ET.
The R&D Day will provide an opportunity to learn more about Vaxxinity’s synthetic peptide vaccine platform and hear insights from neuroscience, migraine and hypercholesterolemia subject matter experts on the current and future treatment landscapes. The event will include presentations from the following guest speakers:
- Brian Fiske, PhD, Co-Chief Scientific Officer, The Michael J. Fox Foundation for Parkinson’s Research
- Dr. Jeffrey L. Cummings, ScD, Vice Chair of Research, University of Nevada Las Vegas Department of Brain Health
- Dr. Stephen Silberstein, Professor, Director, Jefferson Headache Center
- Dr. Rob Scott, former Chief Medical Officer at AbbVie and VP Global Development, Therapeutic Area Head at Amgen
Vaxxinity’s directors and management will provide a business update and discuss development updates from the company’s robust pipeline of synthetic peptide vaccine candidates.
The event will be webcast live and virtual participants may register in advance at this link.
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "potentially," and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, and are based on the current expectations and assumptions of Vaxxinity’s management. Forward-looking statements include statements about the development of a new class of immunotherapeutic vaccines and the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2022 and other reports we file with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Vaxxinity does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.